DRKS00030003
Recruiting
未知
Psychosomatic hybrid rehab
niversität zu Lübeck0 sites120 target enrollmentAugust 11, 2022
ConditionsF33F32F32.0F32.1F32.8F32.9F33.0F33.1F33.4F33.8F33.9F34F38F39F41.0F41.1F41.2F41.3F43F43.0F43.1F43.2F43.8F43.9F48F48.0Recurrent depressive disorderDepressive episodeMild depressive episodeModerate depressive episodeOther depressive episodesDepressive episode, unspecifiedRecurrent depressive disorder, current episode mildRecurrent depressive disorder, current episode moderateRecurrent depressive disorder, currently in remissionOther recurrent depressive disordersRecurrent depressive disorder, unspecifiedPersistent mood [affective] disordersOther mood [affective] disordersUnspecified mood [affective] disorderPanic disorder [episodic paroxysmal anxiety]Generalized anxiety disorderMixed anxiety and depressive disorderOther mixed anxiety disordersReaction to severe stress, and adjustment disordersAcute stress reactionPost-traumatic stress disorderAdjustment disordersOther reactions to severe stressReaction to severe stress, unspecifiedOther neurotic disordersNeurasthenia
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- F33
- Sponsor
- niversität zu Lübeck
- Enrollment
- 120
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age between 18 and 60 years, F\-diagnoses (see above); employment subject to social insurance contributions; unemployed; DRV\-Bund, DRV\-Rheinland, DRV Knappschaft\-Bahn\-See; access to internet; technical skills; declaration of consent
Exclusion Criteria
- •Rehabilitants without appropriate technical infrastructure (digital terminal, Internet), insufficient language skills, lack of consent to participate; retired; alcohol or drug addiction; high suicide risk
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentAlcoholic hepatitisMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2020-004534-38-DEDURECT Corporation300
Active, not recruiting
Phase 1
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentAlcoholic hepatitisMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2020-004534-38-FRDURECT Corporation300
Recruiting
Phase 3
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast CancerBreast cancerBreast carcinoma10006291NL-OMON51870Merck Sharp & Dohme (MSD)24
Active, not recruiting
Not Applicable
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseSecondary hyperparathyroidism in subjects with chronic kidney diseaseMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 17.0Level: LLTClassification code 10020706Term: Hyperparathyroidism NOSSystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Diseases [C] - Symptoms and general pathology [C23]EUCTR2012-002805-23-ATKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)500
Active, not recruiting
Phase 1
A phase 3 randomised, double-blind, placebo-controlled efficacy and safety study funded by Furiex Pharmaceuticals. The purpose of this study is to find out if a new investigational drug called JNJ-27018966 is safe and effective as a treatment for diarrhea-predominant Irritable Bowel Syndrome (IBS-d).Diarrhea-predominant irritable bowel syndromeMedDRA version: 20.1 Level: LLT Classification code 10060845 Term: Diarrhea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1 Level: PT Classification code 10023003 Term: Irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Body processes [G] - Digestive System and Oral Physiological Phenomena [G10]EUCTR2012-001600-38-GBFuriex Pharmaceuticals1,282